The world’s most effective medical cannabis pharmaceutical formulations for the treatment of inflammation-related conditions
DISCLAIMER
This presentation contains “forward-looking” statements, which relate to future events or the anticipated performance of PlantEXT Ltd. (the “Company”) and reflects expectations or beliefs regarding such future events and anticipated performance. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “schedule”, “estimate”, “forecasts”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur” or “be achieved”, or the negative of these words or comparable terminology. By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual performance of the Company to be materially different from any anticipated performance expressed or implied by the forward-looking statements. Such factors include various risks related to the Company’s operations, including, without limitation, fluctuations in currency markets, assets, liabilities, growth rate, changes in government’s policy and regulations etc. There may also be other factors that cause the Company’s performance to not be as anticipated.

The Company neither intends nor assumes any obligation to update these forward-looking statements or information to reflect changes in assumptions or circumstances other than as required by applicable law. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those currently anticipated. Accordingly, readers should not rely on forward-looking statements.

CONFIDENTIAL INFORMATION
This presentation contain confidential information that is proprietary and privileged. Any unauthorized review, reproduction, distribution, copying of, or reliance upon this presentation is strictly prohibited.

PRODUCT NAMES
The names of products shown in this presentation are for illustration purposes only.
Presentation Agenda

- Who is PlantEXT?
- What makes us unique?
- Why focus on inflammation?
- Our early-to-market products
- Our product pipeline
Who Is PlantEXT?
Management Team

Doug Sommerville, M.B.A.
Chief Executive Officer
Former Country Head and Global SVP at Teva Canada and Chairman of the Canadian Generic Pharmaceutical Association
Former Global Vice President at Baxter Healthcare Corporation

Paul Andersen, CPA (Canada, US), CA (Canada), GGMA (US)
Chief Financial Officer
More than 25 years senior/director experience in public and private companies; domestic and international experience with cannabis companies

Tahel Altman, B.Sc., MD
GM R&D and Israel Operations
Graduate of Stanford Biodesign Innovation Fellowship
Founder and leader of ART Health Care Ltd., TopgeniX Inc., SynVaccine Ltd.
Inventor of several pharma and medical device patents

Al Shefsky, JD
President (Canada)
Co-founder of Canadian Licensed Producer Delshen Therapeutics
President at Cannadigm Corp.
Our Team

Management Team

Oded Sagee, Ph.D.
President (Israel)
Founder of PlantEXT Ltd.
Former Department Head of Volcani Centre at ARO

Amir Gissin
Vice President, Communications
Former Israeli Consul General in Toronto and Western Canada;
Director of Public Affairs in Israel’s Ministry of Foreign Affairs

Brenda Zeitlin
Chief Operating Officer
More than 25 years of experience in operations, business development, strategic marketing
Expertise in bringing new products to market
Has taught entrepreneurship at two of Israel’s top universities
Our Team

Board of Directors

Hon. Joe Oliver, PC
Chairman of the Board
Former Minister of Finance and
Minister of Natural Resources
Former President & CEO Investment
Dealers Association
Currently Chairman Echelon Wealth
Partners

Doug Sommerville, M.B.A.
Chief Executive Officer
Former Country Head and Global
SVP at Teva Canada and Chairman
of the Canadian Generic
Pharmaceutical Association
Former Global Vice President at
Baxter Healthcare Corporation

Kevin McGovern
Board Member
Chairman and CEO McGovern
Capital
Founder of SoBe Beverages—
fastest-growing company in the
US (sold to Pepsi)
Co-Chairman, Israel Plant
Sciences

Ittamar Herman LL.B
Board Member
Director of Jewish National Fund
Chairman, 18th Maccabiah
Organizing Committee
Chairman of Kfar Maccabia
Board of Directors

Stan Bharti
Board Member
Executive Chairman of Forbes&Manhattan Inc.
Founded the Bharti School of Engineering in collaboration with Laurentian University

Al Shefsky, JD
President (Canada)
Co-founder of Canadian Licensed Producer Delshen Therapeutics
President Cannadigm Corp.

Oded Sagee, Ph.D.
President (Israel)
Founder of PlantEXT Ltd.
Former Department Head of Volcani Centre at ARO
Our Vision

To develop the world’s most effective anti-inflammatory medical cannabis pharmaceutical formulations to improve the quality of life for patients across the globe.
An overview of PlantEXT

• Unique expertise in developing and commercializing cannabis-based medical extracts and formulations (higher-margin products than commodity-priced flower and oils)
• Proprietary pharmaceutical formulations that treat unmet needs of patients suffering from inflammation-related conditions
• Science-driven intellectual property and products backed by clinical studies
• Early to market with first product in Q2 2019 under exclusive license from Agricultural Research Organization, Volcani Institute of the State of Israel (ARO)
• PlantEXT’s independently developed products to be commercially marketed in Q2 2019
What Makes PlantEXT Unique?
A True Pharma Approach to Cannabis

• Product development focused on treatment for diseases and conditions caused by inflammation
• Fully permitted and equipped independent laboratory facilities in Tel Aviv
• Dedicated and highly qualified PlantEXT researchers, trained at leading cannabis research facilities in Israel
• R&D plans: Expansion of IBD clinical studies; development of IP and products for pain, dermatological conditions and other inflammatory conditions
• Evidence-based clinical support for products
• Speed to market: Streamlined cannabis regulatory pathway compared to traditional pharma
A Targeted Market

• A focus on inflammation helps us optimize our resources for product development.

• We don’t simply provide cannabis oil as a treatment. We create:
  - unique, patent-pending formulas
  - using effective delivery systems
  - targeted to improved outcomes for specific inflammation-related conditions

• Pharmaceutical cannabis – we focus at the molecular level and develop formulations that are not strain dependent – our unique combinations of cannabinoids, terpenes, etc. can be replicated in all geographies around the world where medical marijuana is legal.
How We Add Value

From Commodity to Intellectual Property

- Flower (bud) to oils (extracts)
- Proprietary pharmaceutical formulations for specific therapeutic areas
- Effective delivery systems
- Clinical, evidence-based products and IP

Value
Why Focus on Inflammation?
Inflammatory diseases include a vast array of disorders and conditions that are characterized and caused by inflammation. Examples include allergy, asthma, rheumatoid arthritis, psoriasis, celiac disease, multiple sclerosis, lupus, hepatitis, inflammatory bowel disease, diabetes mellitus type 1, pain and transplant rejection.

“Inflammation has long been a well-known symptom of many infectious diseases, but molecular and epidemiological research increasingly suggests that it is also intimately linked with a broad range of non-infectious diseases, perhaps even all of them”

Inflammatory Diseases

How Does Cannabis Treat Inflammation?

- Decreased intestinal motility
- Decreased gut secretion

- Inhibition of cytokine and chemokine production
- Induction of apoptosis
- T-cell induction
- Inhibition of cell proliferation

- Additionally, joint/muscular pain and psoriasis

- Decreased nausea and vomiting
- Improved appetite
- Improved pain control

- Decreased lower esophageal sphincter relaxation
- Delayed gastric emptying
- Reduced gastric acid secretion

- Improved epithelial wound healing
- Decreased intestinal permeability
Our Early-to-Market Product: a Patent-Pending IBD Formulation
Inflammatory Bowel Disease (IBD) is a group of inflammatory conditions of the colon and small intestine.

- Crohn's disease and ulcerative colitis the most common
- Inflame the lining of the gastrointestinal (GI) tract
- Disrupt the body's ability to digest food, absorb nutrition, and eliminate waste in a healthy manner
- Related to immune-mediated inflammation and genetic factors
What Is the Market for IBD?

The IBD Pharma market is forecast to increase from $8.5 billion US in 2016 to $9.5 billion in 2020.
ARO has patented its proprietary methodology to quantify the anti-inflammatory activity of cannabis extracts on human biopsies and has filed a patent for a composition for the treatment of Inflammatory Bowel Diseases (IBD).

Dr. Koltai and ARO’s world class team of scientists have been conducting cutting-edge research and development in collaboration with leading medical and academic institutions in Israel.

Dr. Koltai is a leading author of more than 70 peer-reviewed publications and 30 book chapters and invited reviews, and is a full professor-grade research scientist at ARO, Volcani Centre, Israel.
PlantEXT has exclusive rights to commercialize ARO’s IBD intellectual property and products globally

- PlantEXT entered license agreement with ARO in 2015
- Exclusive rights to:
  - fund development of medical cannabis intellectual property and products at ARO for the treatment of IBD
  - commercialize ARO’s IBD IP and products globally
- In addition, PlantEXT has a strategic alliance with a well-established pharma company that will manufacture the first IBD product for PlantEXT at its GMP-certified facility in Israel
- IBD product to be distributed to pharmacies by a leading Israeli pharma company beginning in Q1 2019

From left, PlantEXT Chairman Joe Oliver with Prof. Hinanit Koltai and Prof. Eli Feinerman, Head of ARO’s Volcani Institute at signing ceremony
Human Biopsy Study

<table>
<thead>
<tr>
<th>Treatment</th>
<th>% Reduction of inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plant^{EXT} Cannabis extract</td>
<td>89.5</td>
</tr>
<tr>
<td>Plant^{EXT} Cannabis active fraction</td>
<td>96.8</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>42.7</td>
</tr>
</tbody>
</table>

- Study began in March 2016
- Biopsies were taken from 54 IBD patients, (23 UC, 26 CD and 5 healthy)
- Anti-inflammatory activity examined for cannabis extract, fractions and compounds on biopsies
Product Pipeline
Inflammatory Bowel Disease

Our Early-to-Market Product: IBD Formulation

• Currently, patent pending on unique, clinically tested IBD formulation
• Demonstrated anti-inflammatory results—backed by clinical studies
• Human biopsy study showed more than 2x reduction in inflammation compared to corticosteroid treatment
• Product to provide prophylactic use to prevent/reduce inflammation and maintain remission
Our team of experts is actively testing for additional treatments.

- PlantEXT’s independent R+D facility is located within a world class lab facility in Tel Aviv
- Access to leading technical professionals—including former Teva experts in chemistry, formulation and delivery systems
- Access to advanced analytical equipment, ability to rapidly develop new formulations
- Fully permitted facility allows the ability to conduct research under existing permits with controlled substances
- Currently developing a pipeline of new products for introduction starting in 2019
~7.5 million in US (2.2% of population)—125 million globally—have psoriasis

The most prevalent autoimmune disease in US

Total direct and indirect healthcare costs calculated at over $11.25 billion/year (US)

A review done in 2016 suggested that cannabis can be a useful treatment for psoriasis

A 2017 review that explored the relevance of cannabis in dermatology noted that the relief of itching was one of the most promising roles of topical cannabinoids.

Unique pharmaceutical formula to capture best synergies between active ingredients
• Medical cannabis well accepted as an effective treatment for pain
• Targeted and unique formulas to capture best synergies between active ingredients
• Various dosage forms—oil, topical creams, gel cap
• Global pain management market is under-served by current traditional medicines
• Abuse remains a prevalent and troubling side effect of current pharmaceutical treatments
• Global pain management market was estimated at $60B USD in 2015 and expected to rise to $83B by 2024
PlantEXT in the News

PlantEXT and Israel's Agricultural Research Organization Report Progress on Research Development of Medicinal Cannabis Formulations for Inflammatory Bowel Disease

Panaxia and Rafa sign a collaboration agreement with PlantEXT to research and manufacture the first medicinal cannabis suppositories intended for patients suffering from Inflammatory Bowel Disease (IBD), Crohn's and Ulcerative Colitis.

Business
PlantEXT and Family Secret Execute Joint Venture Agreement to Develop, Produce and Market Topical Medical Cannabis Products

April 29, 2019, 12:00 AM EDT

Cision

Israel's Oshavim Approves Export of Medicinal Cannabis
PlantEXT's proprietary involvement in extraction and medical therapy.

---

PlantEXT
In Summary
In Summary

World-class team and lab facilities allow rapid product development and commercialization

Patented methodology for testing human tissue

Partnership with State of Israel’s ARO
- Exclusive license of intellectual property (“IP”) developed by ARO
- Exclusive worldwide right to commercialize IP

Early mover advantage with patent-pending formulation targeting IBD global pharma market

Higher margin patented cannabis pharma market
- Newly emerging medical market
- 20-year patent protection allows for pricing power and long term revenue stream

Existing hospital and physician relationships through IBD program
Thank You

Douglas Sommerville
Chief Executive Officer
dsommerville@plantext.com
(416) 301-5418